梅奥分期系统在中国原发性轻链型淀粉样变患者中的临床应用价值

OBJECTIVE: To evaluate the usage of Mayo staging system in Chinese patients with primary light chain (LC) amyloidosis. METHODS: Clinical data, treatment and outcome of 162 primary LC amyloidosis patients with Mayo Clinic staging in Peking Union Medical College Hospital from January 2009 to June 2015 were retrospectively analyzed. RESULTS: The median age of 162 patients with Mayo Clinic 2004 stage was 57 (20–81) y, of them 62.3% were male. The number of patients with stage Ⅰ to Ⅲ were 44 (27.2%), 69 (42.6%), and 49 (30.2%), respectively. The median overall survival was not reached, 23 months and 12months in patients with Mayo Clinic 2004 stage Ⅰ, Ⅱ, and Ⅲ, respectively (P<0.001). Among 128 patients with Mayo Clinic 2012 stage, 48 patients (37.5%), 32 patients (25.0%), 32 patients (25.0%) and 16 patients (12.5%) were staged as Mayo Clinic 2012 stage 1 to 4, and the median OS was not reached, not reached, 13 months and 3 months, respectively (P<0.001). CONCLUSION: Mayo Clinic staging systems had important prognostic value in patients with primary LC amyloidosis.